Glucagon Like Peptide 2 Receptor - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2019’, provides in depth analysis on Glucagon Like Peptide 2 Receptor (GLP2R) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Gastrointestinal, Toxicology and Metabolic Disorders under development targeting Glucagon Like Peptide 2 Receptor (GLP2R).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)

- The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects

- The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Adocia SAS

Hanmi Pharmaceuticals Co Ltd

Naia Ltd

PhaseBio Pharmaceuticals Inc

Sosei Heptares

Takeda Pharmaceutical Co Ltd

Tasly Pharmaceutical Group Co Ltd

Therachon AG

Zealand ...

Adocia SAS

Hanmi Pharmaceuticals Co Ltd

Naia Ltd

PhaseBio Pharmaceuticals Inc

Sosei Heptares

Takeda Pharmaceutical Co Ltd

Tasly Pharmaceutical Group Co Ltd

Therachon AG

Zealand Pharma AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glucagon Like Peptide 2 Receptor (GLP2R) – Overview

Glucagon Like ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glucagon Like Peptide 2 Receptor (GLP2R) – Overview

Glucagon Like Peptide 2 Receptor (GLP2R) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Glucagon Like Peptide 2 Receptor (GLP2R) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucagon Like Peptide 2 Receptor (GLP2R) – Companies Involved in Therapeutics Development

Adocia SAS

Hanmi Pharmaceuticals Co Ltd

Naia Ltd

PhaseBio Pharmaceuticals Inc

Sosei Heptares

Takeda Pharmaceutical Co Ltd

Tasly Pharmaceutical Group Co Ltd

Therachon AG

Zealand Pharma AS

Glucagon Like Peptide 2 Receptor (GLP2R) – Drug Profiles

apraglutide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elsiglutide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize GLP2R for Short Bowel Syndrome – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glepaglutide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXG-8 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15912 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Agonize GLP2R for Intestinal Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-7570 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZPGG-72 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucagon Like Peptide 2 Receptor (GLP2R) – Dormant Products

Glucagon Like Peptide 2 Receptor (GLP2R) – Product Development Milestones

Featured News & Press Releases

Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference

Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study

Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome

Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome

Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome

Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide

May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.

Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome

Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland

Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome

Jan 23, 2018: Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.

Jan 22, 2018: Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference

Nov 14, 2017: Recruitment completed in trial to evaluate the optimal dosing frequency for Zealands long-acting GLP-2 analog glepaglutide

Oct 24, 2017: U.S. FDA Grants Orphan Drug Designation to Glepaglutide for the Treatment of Short Bowel Syndrome

Oct 12, 2017: Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Adocia SAS, H1 2019

Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2019

Pipeline by Naia Ltd, H1 2019

Pipeline by PhaseBio Pharmaceuticals Inc, H1 2019

Pipeline by Sosei Heptares, H1 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2019

Pipeline by Therachon AG, H1 2019

Pipeline by Zealand Pharma AS, H1 2019

Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports